NCT05496231 2025-02-03
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
GlaxoSmithKline
Phase 1/2 Completed
Clinical Trials
1 trialsPhase 1/2 × Uterine Cervical Dysplasia × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all